A phase I study of decitabine and rapamycin in relapsed/refractory AML

Leukemia Research

Volumn 37, Issue 12, 2013, Pages 1622-1627

  Liesveld, Jane L ^a   O'Dwyer, Kristen ^a   Walker, Alison ^a   Becker, Michael W ^a   Ifthikharuddin, J J ^a   Mulford, Deborah ^a   Chen, Rui ^b   Bechelli, Jeremy ^a   Rosell, Karen ^a   Minhajuddin, Mohammed ^a   Jordan, Craig T ^a   Phillips, Gordon L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Department of Biostatistics and Computational Biology ^*  (United States)

Author keywords

AML; Decitabine; Phase I; Rapamycin; Refractory; Relapsed

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GENOMIC DNA; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CARCINOGENESIS; CLINICAL ARTICLE; DNA REPLICATION; DRUG DOSE ESCALATION; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; WEIGHT REDUCTION;

EID: 84888131812     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.09.002     Document Type: Article

References (31)

1. Kell J. Treatment of relapsed acute myelogenous leukemia. Rev Recent Clin Trials 2006, 1:103-111.
2. Buchholz S., Dammann E., Stadler M., Krauter J., Beutel G., Trummer A., et al. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 2012, 88:52-60.
3. Yang A.S., Doshi K.D., Choi S.W., Mason J.B., Manari R.K., Gharybian V., et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006, 66:5495-5503.
4. Kantarjian H.M., Thomas X.G., Dmoszynska A., Wierzbowska A., Mazur G., Mayer J., et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677.
5. Cashen A.F., Schiller G.J., O'Donnell M.R., DiPersio J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
6. Blum W., Garzon R., Kilsovic R.B., Schwind S., Walker A., Geyer S., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010, 107:7473-7478.
7. Ganguly S., Amin M., Divine C., Aljitawl O.S., Abhyankar S., McGuirk J.P. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT). Ann Hematol 2013, 92:549-550. [Letter].
8. Blum W., Schwind S., Tarighat S.S., Geyer S., Eisfeld A.-K., Whitman S., et al. Clinical and pharmacodynamics activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012, 119:6025-6031.
9. Samuels Y., Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006, 20:911-928.
10. Min Y.H., Eom J.I., Cheong J.W., Maeng H.O., Kin J.Y., Jeung H.K., et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003, 17:995-997.
11. Horn S., Bergholz U., Jucker M., McCubrey J.A., Trumper L., Stocking C., et al. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene 2008, 27:4096-4106.
12. Martinellii A.M., Tazzari P.L., Evangellisti C., Chiarini F., Blalock W.L., Billi A.M., et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007, 14:2009-2023.
13. Park S., Chapuis N., Bardet V., Tamburini J., Gallay N., Willems L., et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 2008, 22:1698-1706.
14. Perl A.E., Kasner M.T., Tsai D.E., Vogl D.T., Loren A.W., Schuster S.J., et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009, 15:6732-6739.
15. Recher C., Beyne-Rauzy O., Demur C., Chicanne G., Dos Santos C., Mansat-De Mas V., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
16. Nishioka C., Ikezoe T., Yang J., Koeffler H.P., Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 2008, 22:2159-2168.
17. Chakraborty S., Mohiyuddin S.M., Gopinath K.S., Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 2008, 8:163-169.
18. Xu Z., Wang M., Wang L., Wang Y., Zhao X., Rao Q., et al. Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res 2009, 33:891-897.
19. Faderl S., Ravandi F., Huang X., Wang X., Jabbour E., Garcia-Manero G., et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012, 118:4471-4477.
20. Vardiman J.W., Harris N.L., Brunning P.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
21. Chesson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Setey E.H., et al. Revised recommendations of the International Working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
22. Plimack E.R., Kantarjian H.M., Issa J-P. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 2007, 48:1472-1481.
23. Blum W., Klisovic R.B., Hackanson B., Liu Z., Liu S., Devine H., et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007, 25:3884-3891.
24. Xu Q., Simpson S.E., Scialla T.J., Bagg A., Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
25. Misaghian N., Ligresti G., Steelman L.S., Bertrand F.E., Basecke J., Libra M., et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009, 23:25-42.
26. Tamburini J., Chapuis N., Bardet V., Park S., Sujobert P., Willems L., et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008, 111:379-382. 2007.
27. Ponticelli C., Passerein P. Gastrointestinal complications in renal transplant recipients. Transpl Int 2005, 18:643-650.
28. Willems L., Chapuis N., Puissant A., Maciel T.T., Green A.S., Jacque N., et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012, 26:1195-1202.
29. Altman J.K., Sassano A., Kaur S., Glaser H., Kroczynska B., Redig A.J., et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011, 17:4378-4388.
30. Chapuis N., Tamburini J., Green A.S., Vignon C., Bardet V., Neyret A., et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010, 16:5424-5435.
31. Sanchez-Abarca L., Guitierrez-Cosio S., Santamaria C., Caballero-Velazquez T., Bianco B., Herrero-Sanchez C., et al. Immunomodulatory effect of 5-azacytidine (5-azaDc): potential role in the transplantation setting. Blood 2010, 115:107-121.